Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Conditions are right for biopharma M&A to break out

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon May 28, 2023 8:44pm

118 Views

Post# 35468174

RE:RE:RE:RE:RE:RE:RE:Conditions are right for biopharma M&A to break out

Ask Carey Johnson (Geneman) if I been taking things out of context now Buckhenry or should I have just brushed-off the soft-bashing that he, you and Quentin30 have been trying to accomplish.

<< Previous

Bullboard Posts

Next >>

TELUS adds 347K customers in Q3